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Abstract: Oxidative stress develops as a response to injury and reflects a breach in the cell’s antioxidant
capacity. Therefore, the fine-tuning of reactive oxygen species (ROS) generation is crucial for preserving
cell’s homeostasis. Mitochondria are a major source and an immediate target of ROS. Under
different stimuli, including oxidative stress and impaired quality control, mitochondrial constituents
(e.g., mitochondrial DNA, mtDNA) are displaced toward intra- or extracellular compartments.
However, the mechanisms responsible for mtDNA unloading remain largely unclear. While shuttling
freely within the cell, mtDNA can be delivered into the extracellular compartment via either extrusion
of entire nucleoids or the generation and release of extracellular vesicles. Once discarded, mtDNA may
act as a damage-associated molecular pattern (DAMP) and trigger an innate immune inflammatory
response by binding to danger-signal receptors. Neuroinflammation is associated with a large
array of neurological disorders for which mitochondrial DAMPs could represent a common thread
supporting disease progression. The exploration of non-canonical pathways involved in mitochondrial
quality control and neurodegeneration may unveil novel targets for the development of therapeutic
agents. Here, we discuss these processes in the setting of two common neurodegenerative diseases
(Alzheimer’s and Parkinson’s disease) and Down syndrome, the most frequent progeroid syndrome.
Keywords: Alzheimer’s disease; cytokines; DAMPs; Down syndrome; endo-lysosomal
system; extracellular vesicles; mitochondrial DNA; mitochondrial quality control; mitophagy;
Parkinson’s disease
1. Introduction
Oxidative stress and neuroinflammation are pathologic signatures of neurodegeneration [1,2].
Cells of innate immunity are a source of reactive oxygen species (ROS) within the central nervous
system (CNS), with oxidant overproduction being a candidate mechanism in neuronal damage and
loss via neuroinflammation [3,4]. The molecular determinants of immune-mediated oxidative stress
and neurodegeneration remain poorly understood. However, microglia activation is considered to be
a major contributor [3,5].
Microglial cells are CNS macrophages that ensure homeostasis of the nervous tissue by clearing
out damaged neurons and limiting the spread of infections. As a first line of defense against microbes,
this macrophage population triggers inflammation via cytokine production and instigates ROS
generation [6]. However, a long-standing pro-inflammatory and pro-oxidant environment sustained
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by persistent microglia activation is detrimental as it may contribute to neurodegeneration. This is
particularly relevant in the context of Alzheimer’s (AD) and Parkinson’s disease (PD) [7,8]. Metabolic
changes in microglia have also been associated with a state of chronic low-grade inflammation observed
during aging (i.e., inflamm-aging) [9,10]. Oxidative stress is also a hallmark of progeroid conditions.
For instance, Down syndrome (DS), caused by a genetic imbalance of chromosome 21 which contains
genes coding for enzymes implicated in oxidative stress (e.g., Cu/Zn superoxide dismutase, SOD1),
is characterized by a breach in antioxidant defenses [11,12]. What is more relevant, people with DS,
among other clinical features, show cognitive deficits and are prone to developing AD [13]. Hence,
a deeper understanding of the molecular determinants of progeroid conditions may provide relevant
insights into the pathophysiology of age-related neurodegenerative conditions as they may share
common roots.
Mitochondria are a major source of ROS as a byproduct of the electron transport chain (ETC)
activity [14]. These organelles are also a direct ROS target [14]. Oxidative stress-related mitochondrial
disarrangements have been indicated as contributors to neurodegeneration [15]. Only recently, it has
emerged that, apart from their relevance to cellular energy provision and ROS signaling, mitochondria
participate in inflammation by triggering a danger signaling response [16,17]. In particular, in response
to various stressors, mitochondrial DNA (mtDNA) can be displaced into intra- or extracellular
compartments [18]. Albeit the mechanisms whereby mtDNA is unloaded from mitochondria are
largely unclear, several lines of evidence indicate that mtDNA can be shuttled toward the extracellular
compartment via the generation and release of extracellular vesicles (EVs) [18–21]. Along with mtDNA
and other mitochondrial components, cell-free intact mitochondria have been found in the blood of
healthy people [21]. What is more, these organelles show functional competence [21]. Once released,
mitochondrial constituents, in particular mtDNA, may act as damage-associated molecular patterns
(DAMPs) that can be sensed as non-self molecules and trigger an innate immune inflammatory response
by binding to danger signal receptors [16,17].
Further to this, mitochondria take part in a highly interconnected and dynamic network
of organelles and structures, including the endoplasmic reticulum, lysosomes, and the actin
cytoskeleton [22,23]. Mitochondrial plasticity is also influenced by energy-sensing mediators
including insulin, insulin-like growth factor 1 (IGF1), mechanistic target of rapamycin (mTOR),
AMP-activated protein kinase (AMPK), and Sirtuins [24]. Metabolic alterations arising from
deregulated nutrient sensing have been reported in the setting of neurodegeneration in conjunction with
mitochondrial dysfunction and oxidative stress [24]. Indeed, mitochondrial homeostasis relies upon
the integrity of intracellular organelle networks, inter-mitochondrial content exchange, and integration
of metabolic signaling [22,24]. Via inter-mitochondrial junctions, adjacent organelles coordinate
membrane cristae remodeling [25], while mitochondrial fusion allows matrix and intermembrane
space content (i.e., proteins, mtDNA, and metabolites) to be mixed between organelles to avoid focal
accumulation of damaged constituents [26]. Recently, tubular protrusions, referred to as mitochondrial
nanotunnels, have been identified as novel structures enabling mitochondrial interconnections [27].
Via these structures, mitochondria that are immobilized within post-mitotic tissues (e.g., skeletal
muscle, myocardium) and limited in their fusion events, may communicate over long distances [27].
Finally, Golgi-derived vesicles have also been shown to participate in mitochondrial dynamics and
homeostasis [28].
Neuroinflammation is associated with a large set of neurological disorders for which mitochondrial
derived vesicles (MDVs) may represent a common thread supporting disease progression. The analysis
of these pathways may help clarify the events linking cell dyshomeostasis with peripheral changes
that could even precede neuroinflammation. Indeed, EVs are shuttle systems whereby cells interact
or remove unwanted materials [29]. In the setting of failing mitochondrial fidelity pathways, MDVs
serve a further layer of mitochondrial quality control (MQC) orchestrated by mitochondrial–lysosomal
crosstalk [20]. The clearance of dysfunctional organelles via MDVs involves the release of noxious
material that can potentially trigger sterile inflammation. This response is part of innate immunity and
Antioxidants 2020, 9, 647 3 of 21
operates through the binding and activation of membrane or cytoplasmic pattern recognition receptors
(PRRs) (reviewed in [30]). Indeed, mtDNA possesses hypomethylated CpG motifs that are similar to
those of bacterial DNA and are recognized by PRRs [30].
In this context, a comprehensive profiling of neuronal-derived DAMPs, including those transported
within MDVs, offers the opportunity to shed light on the complex regulatory network governing
intracellular homeostasis. This knowledge may also allow deciphering peripheral changes that
accompany neurodegeneration. The relevance of EVs in shuttling DAMPs resides in the unique
packaging of the information contained, which confers protection of the cargo and delivery of multiple
messengers in a paracrine and endocrine fashion. The exploration of these non-canonical pathways
arising from mitochondrial dysfunction and contributing to neurodegeneration may unveil novel
targets for the development of therapeutics. Here, we discuss these pathways in the setting of two
common neurodegenerative diseases (AD and PD) and DS, the most frequent progeroid syndrome.
2. Mitochondrial Quality Control, mtDNA Release, and Inflammation
2.1. Failing Mitochondrial Quality Control and mtDNA Release
A set of MQC processes spanning from mitochondriogenesis to mitochondrial plasticity, autophagy,
and mitochondrial unfolded protein response (UPRmt) are in place to safeguard cell and organismal
homeostasis [20]. Mitochondrial dynamics rely upon coordinated cycles of fusion and fission.
An adequate mitochondrial plasticity is crucial for matching cellular energy demands and diluting
mitochondrial damage along the network [26]. Changes in mitochondrial dynamics are sensed and
integrated by a nutrient-sensing signaling pathway that modulates mitochondrial functions via a set of
energy-sensing mediators (e.g., insulin, IGF1, mTOR, AMPK, Sirtuins) [24]. When mitochondria become
bioenergetically incompetent, mitochondrial hyper-fission segregates damaged organelles from the
network and primes them for subsequent disposal via mitophagy [26]. Concomitantly, mitochondrial
biogenesis, through generating new organelles, maintains an adequate pool of functional mitochondria
within the cell [26]. Mitochondrial epigenetic regulation (i.e., mito-epigenetics) is also relevant for
proper cell signaling, as shown by the existence of specific patterns of mtDNA methylation associated
with susceptibility to developing neurodegenerative diseases [31]. Mito-epigenetic control over
genes encoding mitophagy factors has also been implicated in longevity via modulation of UPRmt
signaling [32,33].
Failing MQC is a major contributor to aging and associated conditions, including
neurodegeneration [24]. In this context, circulating mtDNA is increasingly acknowledged as a
pivotal mediator linking mitochondrial dysfunction to inflammation [30,34,35]. Of all mitochondrial
components, mtDNA is the most susceptible to be sensed as a “non-self” molecule due to the presence
within its structure of aberrant/devoid CpG methylation motifs that can trigger inflammation [34–40].
Fragmented mtDNA as well as circular double-stranded or linear single-stranded mtDNA molecules
and nucleoids have been found in the human plasma in various disease conditions [37,38,41–43].
However, the mechanisms regulating the displacement of mtDNA into the extracellular compartment
are still fuzzy. Among the most accredited hypotheses, an unconventional unloading of damaged
mtDNA during stressful conditions seems to occur as part of the danger signaling response to support
cell’s homeostasis [16,17].
Along with other insults, the installment of oxidative stress as a result of ROS overproduction
mainly by mitochondria is a known trigger of inflammation [44]. The activation of redox-sensitive
inflammatory pathways has been reported in case of altered mitochondrial calcium metabolism, iron
mishandling, and higher ROS production [45,46]. ROS bursts are a major pro-inflammatory stimulus
per se via activation of nuclear factor κB (NF-κB) [47]. However, mitochondrial ROS also participate
in other cellular processes including the activation of mitochondrial permeability transition pore
(mPTP), dysregulation of mitophagy, imbalances in mitochondrial dynamics, and programmed cell
death [48]. These processes represent potential routes for mtDNA displacement following ROS burst
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as evidenced by the finding of oxidized mtDNA fragments outside of mitochondria in the setting of
several metabolic diseases [43,49–53] (Figure 1).
Figure 1. Schematic representation of the pathways involved in mitochondrial DNA unloading.
Under several stressors (e.g., mitochondrial dysfunction and consequent reactive oxygen species (ROS)
production, viral and bacterial infections), several types of damage are inflicted to mitochondrial DNA
(mtDNA) and a set of signaling pathways are activated to promote mitochondrial recovery or demise
depending on the damage severity. (1) In the setting of ROS bursts, mtDNA oxidation and fragmentation
occur concomitant with mitochondrial permeability transition pore (mPTP) opening. If the extent
of damage overwhelms the mitochondrial quality control system, persistent mPTP opening allows
extrusion of oxidized mtDNA fragments into the cytosol. Meanwhile, the deployment of apoptosis via
Bax/Bak signaling enables the extrusion of mtDNA nucleoids consisting of mitochondrial transcription
factor A-bound mtDNA. (2) Transient opening of mPTP and ROS production trigger mitochondrial
fission and mitophagy to clear dysfunctional mitochondria. Damaged organelles are sequestered into
autophagosomes that subsequently fuse with lysosomes for content disposal. Herein, a set of DNases
execute mtDNA cleavage. (3) Hyperfragmented or hyperfused mitochondria also deliver mtDNA into
the cytosol from which it can be extruded into the extracellular space through unknown mechanisms.
(4) If mitochondria are only mildly damaged, mtDNA and other mitochondrial constituents can be
shuttled outside the cell via extracellular vesicles (EVs). EVs of mitochondrial origin (i.e., mitochondrial
derived vesicles) may fuse with multivesicular bodies (MVBs) and deliver their cargo in the extracellular
space for signaling purposes. (5) Following cell injury or necrosis, the damaged plasma membrane
may represent a route for the delivery of mtDNA and other cellular components outside of the cell.
Abbreviations: LC3, microtubule-associated protein 1A/1B-light chain 3; PARL, presenilin-associated
rhomboid-like; PINK, phosphatase and tensin homolog-induced kinase 1; TIM, translocase of the inner
mitochondrial membrane; TOM, translocase of the outer mitochondrial membrane.
Under oxidative stress conditions, mPTP opening induces a transient increase of inner
mitochondrial membrane permeability which allows the release of ions, small molecules,
and mitochondrial matrix components, including mtDNA [54]. Instead, irreversibly damaged
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and uncoupled mitochondria undergo permanent mPTP opening which also has been implicated in
mtDNA extrusion [55]. In both cases, the release of mtDNA via mPTP from isolated mitochondria
is blunted by the administration of ciclosporin A (CSA) [42,56]. In vitro experiments have clarified
that, under oxidative stress, the unloading of mtDNA fragments is attributable to permanent mPTP
activation [42,56]. Indeed, in isolated mitochondria exposed to oxidative stress, the release of mtDNA
but not its fragmentation is attenuated by CSA [42,56].
Along with mPTP opening, oxidative stress can also activate mitophagy for organelle
disposal [57,58]. Mitophagy involves the engulfment of dysfunctional mitochondria into
autophagosomes, which then fuse with lysosomes for organelle degradation [59]. Derangements
of the mitophagic machinery may result in the accrual of damaged mitochondrial constituents that
can follow alternative clearance routes. Mitochondrial components can be released into the cytosol
or in the extracellular space where they trigger an innate immune response [39,52,60–62]. Of note,
any insults overwhelming the mitophagic process can induce inflammation [60,61]. Hence, the cell’s
ultimate fate depends on the severity of the inflammatory response and the efficiency of cellular
quality control systems. While moderate inflammatory stimuli and defective cellular repair may trigger
apoptosis, in the context of persistent inflammation, mitochondrial dysfunction and ROS-induced
necrosis may ensue [63]. Indeed, mildly damaged mitochondria can trigger a transient mPTP
opening [57,58]. Instead, apoptosis is executed when mitochondrial damage is too severe and/or
mitophagy is overwhelmed [57,64]. In the case of programmed cell death, the activation of the Bax/Bak
pathway may induce permeabilization of the outer mitochondrial membrane with the formation of
pores that, under prolonged stress, become deeper until reaching the inner mitochondrial membrane.
Via these structures, mtDNA nucleoids (i.e., mtDNA complexed with the mitochondrial transcription
factor A) can be displaced into the cytosol [37,38,65]. Altered mitochondrial dynamics have also been
associated with mtDNA-driven inflammation [34–36,39,40]. In particular, preclinical models of optic
atrophy 1 ablation and dynamin related protein 1 (Drp1) overexpression show hyper-fragmented
mitochondria and giant mtDNA nucleoids outside of mitochondria that are able to trigger an immune
response [66].
Emerging evidence indicates that the release of EVs from mitochondria (MDVs) occurs independent
of mitochondrial depolarization, autophagy, or mitochondrial fission [67]. Indeed, MDVs are generated
also in cells lacking autophagy-related serine/threonine kinase gene 5, Beclin-1 or the endolysosomal
regulator Ras-related in Brain protein 9 (RAB9) as well as in cells silenced for DRP1 [67]. However,
MDV biogenesis requires priming by the mitophagy factors, phosphatase and tensin homolog-induced
kinase 1 (PINK1) and Parkin [68]. Therefore, the release of MDVs may represent a complement
to mitophagy for MQC when canonical degradative pathways are overwhelmed or impaired [69].
A proposed mechanism for MDV formation involves the accrual of damaged mitochondrial components
in proximity of mitochondrial membranes under oxidative stress conditions [68]. This event, along
with cardiolipin oxidation, may inflict curvatures-like alterations to mitochondrial membranes that are
thought to compete with the activity of import channels [68]. Following the formation of membrane
curvatures, the accumulation of PINK1 at the outer mitochondrial membrane and ubiquitination and
recruitment of Parkin occur [68]. A set of unidentified proteins would finalize the process, eventually
culminating in the release of a vesicle [68]. Hence, all cell constituents, including those of mitochondrial
origin, may potentially be extruded into the circulation as DAMPs in the form of cell-free molecules or
packaged within vesicles [19].
2.2. mtDNA Release and Inflammation
Among mitochondrial DAMPs that can be released by the cell, mtDNA is a potent trigger of
the innate immunity response due to its bacterial ancestry and the presence of hypomethylated CpG
motifs [70,71]. Indeed, mtDNA instigates inflammation via the interaction with PRRs, including
toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRPs),
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and the cyclic GMP/AMP synthase–stimulator of interferon genes (cGAS–STING) systems [72,73]
(Figure 2).
Figure 2. Signaling pathways whereby damaged-associated molecular patterns can trigger inflammation.
Failing mitochondrial quality control processes may lead to intracellular accrual of damaged components
and their release as damaged-associated molecular patterns (DAMPs). Acting as a DAMP, oxidized
mitochondrial DNA (mtDNA) either in the form of mitochondrial transcription factor A-bound nucleoids
(green circles) or free mtDNA (red circles) can trigger inflammation via interacting with (1) toll-like
receptors (TLRs), (2) nucleotide-binding oligomerization domain (NOD)-like receptor family pyrin domain
containing 3 (NLRP3) inflammasome, and (3) cytosolic cyclic GMP/AMP synthase (cGAS)–stimulator
of interferon genes (STING) DNA-sensing system. Abbreviations: IFN, interferon; IL, interleukin; IRF-1,
interferon regulatory factor 1; mtDNA, mitochondrial DNA; NF-κB, nuclear factor κB; ROS, reactive
oxygen species; TBK1, TRAF family member-associated NF-κB activator (TANK)-binding kinase 1; TNF-α,
tumor necrosis factor alpha.
Mitochondrial DNA can engage the TLR pathway by binding TLR9 at the endo-lysosomal
level. As a consequence of this interaction, TLR9 recruits the innate immune signal transduction
adaptor myeloid differentiation primary response 88 (MyD88) that activates the mitogen-activated
protein kinase and instigates inflammation via NF-κB signaling [74–76]. Through the same pathway,
neutrophil recruitment and NF-κB-triggered inflammation occur [74–76]. Alternatively, mtDNA can
induce inflammation via inflammasome and cGAS–STING activation within the cytosol [77–81].
NLRP3 is the best characterized multi-subunit inflammasome system. Upon activation via binding
to adaptor molecules, NLRP3 engages caspase-1 and promotes caspase-1-dependent cleavage and
activation of interleukin (IL) 1 and 18 [82]. NLRP3-induced inflammation has been observed in
several conditions, including AD (reviewed in [83]). The synergistic activation of redox-sensitive
inflammation and inflammasome concurs to reinforcing the inflammatory response [84]. The molecular
determinants linking inflammasome activation to sterile inflammation are unclear; though, the presence
of bacterial-like motifs in mtDNA are sensed by NLRs [85]. NLRP3 activation has also been indicated
to act as an upstream checkpoint of the innate immune system during the deployment of sterile
inflammation. Indeed, NLRP3 facilitates mPTP opening, thereby contributing to mtDNA release [62].
Hence, a self-sustaining circle of mitochondrial dysfunction, ROS bursts, and mtDNA damage triggered
by NLRP3 activators has been hypothesized [78]. Oxidized mtDNA, once released, is preferentially
bound and may serve as the ultimate NLRP3 ligand [78], thus confirming the crucial role played by
ROS in inflammasome activation [77].
The cGAS–STING DNA-sensing pathway also contributes to sterile inflammation as part of an
innate immunity response driven by mtDNA [73]. In particular, the binding of mtDNA to cGAS
induces a conformational change that enables the recruitment of STING protein at the endoplasmic
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reticulum and the subsequent phosphorylation of the transcription factor, interferon (IFN) regulatory
factor 3 (IRF-3) via TRAF family member-associated NF-κB activator (TANK)-binding kinase (TBK).
Once activated, IRF-3 triggers the expression of type I and III IFN and IFN-stimulated nuclear gene.
The activation of cGAS–STING DNA pathway by mtDNA has been observed in the setting of cell
death, mitochondrial stress, and viral infections [79–81].
The cGAS–STING-DNA driven inflammation has been implicated in neurodegeneration following
mitophagy impairment [52]. Higher circulating levels of proinflammatory IL6 and INFβ were found
in Pink and Parkin knockout mice when challenged with exhaustive exercise compared with wild-type
littermates [52]. Notably, this response is blunted by deleting STING or by administering INFα/β
receptor-blocking antibody, thus suggesting that the accrual of dysfunctional mitochondria may be
necessary for the release of mtDNA to drive inflammation in PD [52].
Following the view of altered quality control as a source of DAMPs, in the next paragraphs,
we discuss the main literature on mitophagy impairment and mtDNA dyshomeostasis in the setting of
two common neurodegenerative diseases (AD and PD) and DS, the most frequent progeroid syndrome.
3. Alzheimer’s Disease
AD is the most common age-related dementia and is featured by neuronal loss mainly in the
neocortex and the hippocampus [28]. The deposition of extracellular plaques consisting of amyloid
beta (Aβ) aggregates and intracellular neurofibrillary tangles are major histopathological features of
the disease [28]. The deposition of these noxious proteins in the brain is associated with and contribute
to cognitive impairment [86]. Aβ aggregates are produced via proteolytic cleavage of the C-terminus of
the amyloid precursor protein (APP) by β- and γ-secretase, while neurofibrillary tangles mainly consist
of hyperphosphorylated and misfolded Tau protein [86]. Although AD cases are mostly sporadic,
mutations in APP or presenilin, the catalytic subunit of γ-secretase, have been found in familial forms
of AD [87].
Following amyloid plaque deposition, the activation of microglia and the release of inflammatory
cytokines, including IL1β, IL6 and tumor necrosis factor alpha (TNF-α), have been documented in
AD [88]. A role for these inflammatory markers in inter- and intracellular signaling in microglia and
astrocytes has been hypothesized in AD [89]. Indeed, in the absence of efficient intracellular quality
control [90], the persistence of damaged components and local inflammation may induce neurotoxicity
and favor the generation of Aβ peptides [88].
Alterations of the endo-lysosomal system contribute to the pathogenesis of AD. Aggregates of Aβ
peptides, in particular the most pathogenic Aβ42 aggregate, have been detected in the soma of neurons
at the level of lysosomes or lysosome-derived components [91]. Moreover, enlarged and dysfunctional
multivesicular bodies (MVBs), a specialized type of late degradative endosome, have been described
in neurons from AD transgenic mice in the presence of bulky levels of Aβ42 [92]. Such an impairment
was found to affect the whole endo-lysosomal system as Aβ accrual was also detected in the enlarged
endocytic compartment [92]. Moreover, following MVB dysfunction, an increased APP secretion occurs
in the extracellular compartment of these transgenic mice [92]. The endosomal compartment is also a
hub for the intracellular trafficking of APP by hosting the activity of the β-site APP-cleaving-enzyme,
which is involved in amyloid plaque generation [93]. Indeed, a retromer complex is operative to allow
retrograde transport of APP from endosomes to the trans Golgi network and reduces Aβ production [94].
Instead, impaired retromer complex activity has been involved in AD pathogenesis [94].
Mitochondrial dysfunction and associated oxidative stress have been implicated in AD
pathophysiology. More specifically, decreases in neuronal mtDNA copy number and higher mtDNA
heteroplasmy have been described in post-mortem brains of people with AD [95,96]. Off-target
reads from high-depth whole exome mtDNA sequencing further confirmed the presence of lower
mtDNA content in the brain of persons with AD [97]. Moreover, a focal accumulation of iron was
detected in several brain areas at sites of AD lesions, lending further support to the hypothesis of
redox-generated free radicals as relevant contributor to AD [98]. Age-associated iron dyshomeostasis
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has also been associated to loss of mtDNA stability in human skeletal muscle following oxidative
stress [46]. More relevant is the observation that oxidative damage to mitochondrial proteins and
DNA is an early event in AD, thus suggesting a role for oxidative stress in disease progression [99,100].
Aβ peptide aggregates and neurofibrillary tangles have been implicated in mitochondrial dysfunction as
these aberrant proteins can bind to proteins of the mitochondrial import machinery, thereby impairing
mitochondrial homeostasis [101]. The interaction of these proteins with mitochondria is detrimental
to the ETC activity and results in increased ROS production [102]. Mitochondrial dysfunction and
oxidative stress have also been associated with mitochondrial localization of fragments of APOE4, the E4
variant of apolipoprotein E, which is the main susceptibility gene for sporadic AD, in hippocampal
neurons [103,104].
Although mitochondrial dysfunction may occur as a primary organelle deficit, aberrant
mitochondria can also stem from defective quality control mechanisms, especially mitophagy. In
this context, neuronal bioenergetic failure may be linked to inflammation and neuronal loss [105].
Indeed, the generation of Aβ plaque and phosphorylated-Tau (p-Tau) may install a vicious circle
between defective mitophagy and mitochondrial dysfunction, ultimately leading to neuronal
disruption [105–107]. This may ensue from impaired mitochondrial proteostasis via disarrangements
of the UPRmt machinery and may represent a link between mitochondrial dyshomeostasis and Aβ
proteotoxicity [108]. In this context, the activating transcription factor associated with stress 1 (ATFS-1)
may play a relevant role [109]. Indeed, ATFS-1 is either translocated into the mitochondrial matrix
to inhibit the UPRmt or relocated into the nucleus to trigger mitochondrial turnover depending on
organelle health [109]. An altered expression of the mitophagy receptor disrupted-in-schizophrenia 1
(DISC1) has been found in AD patients, transgenic AD mice model, and Aβ-treated cultured cells [110].
DISC1 promotes mitophagy via binding to microtubule-associated proteins 1A/1B light chain 3 and by
protecting synaptic plasticity from Aβ accumulation-induced toxicity [110].
Further support to a role for defective mitophagy in AD pathogenesis is lent by the positive
effect of pharmacological restoration of mitophagy on cognitive dysfunction and Aβ proteinopathy in
APP/PS1 mice [111]. Moreover, a reduced Tau phosphorylation and mitigation of microglia-induced
inflammation have been observed following pro-mitophagy pharmacological treatments [106].
Mitophagy derangements and consequent mitochondrial dysfunction in AD may sustain the extrusion
of dysfunctional mitochondrial constituents followed by stimulation of innate immunity [72,73].
Mitochondrial DAMPs have been identified as part of circulating EVs in age-related conditions,
including neurodegeneration [112,113]. Should this pathway also be operative in AD, it may help
explain the installment of systemic inflammation in the context of mitochondria dysfunction in
AD [114]. In-depth characterization of EVs cargo may also shed light onto the pathways responsible
for translocation of Aβ42, T-Tau, P-Tau, and neurofilament light polypeptide into the circulation in
AD [115].
4. Parkinson’s Disease
PD is the second most common neurodegenerative disorder affecting older adults [116].
The progressive loss of dopaminergic neurons of the substantia nigra pars compacta and dopamine
depletion in the striatum characterize PD [117]. These histopathological and biochemical features
manifest as motor (i.e., bradykinesia, postural instability, rigidity, and tremor) and non-motor signs
and symptoms (e.g., constipation, depression, sleep disorders, cognitive dysfunction) [117].
Neuroinflammation is also a feature of PD. Recently, the chemokine fractalkine (CX3CL1), mainly
expressed by neurons, has been indicated as a candidate biomarker for PD [118]. CX3CL1 is a
modulator of microglial activity that binds to a G-protein-coupled receptor [118] and is responsible for
the communication between neurons and glial cells [118]. Along with this, peripheral inflammation,
defined by higher circulating levels of IL8, macrophage inflammatory protein (MIP)-1β and by lower
concentrations of IL9 and MIP-1α, has been described in older adults with PD [119].
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Among the pathogenic mechanisms of neurodegeneration in PD is the accrual of aberrant
α-synuclein in dopaminergic neurons, a major component of Lewy bodies, that impairs the activity
of mitochondrial complex I [120]. Notably, this inhibitory function, together with α-synuclein
overexpression and mutations in genes coding for the mitochondrial regulators Parkin, PINK1,
and protein deglycase DJ-1 have been associated with higher ROS production in PD [121,122].
Within this pro-oxidant environment, α-synuclein concurs to promoting oxidative stress, which, in turn,
promotes α-synuclein aggregation, thereby installing a vicious circle that ultimately contributes to
neurodegeneration [123–126]. Hence, mitochondrial dysfunction has been deeply implicated in the
pathogenesis of familial PD [127]. As a proof of concept, the administration of the synthetic organic
compound 6-hydroxydopamine in rodents has shown to be a valuable oxidative stress model for PD
as its neurotoxicity mimics many of the hallmarks of PD [128].
The involvement of mitochondrial dysfunction in PD was first hypothesized based on the
effects of the prodrug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in people with drug
addiction [128]. Upon blood-brain barrier crossing and uptake by astrocytes, MPTP is converted
into 1-methyl-4-phenylpyridinuim (MPP+), a substrate for dopamine transporter that is selectively
uploaded by dopaminergic neurons [128]. Here, MPP+ inhibits the mitochondrial complex I and
induces PD-like signs and symptoms [128]. Furthermore, a defective mtDNA homeostasis, including
the accumulation of large deletions, has been detected in neuronal cells of the substantia nigra of people
with PD [129–131]. ROS production in midbrain cells also arises from dopamine metabolism and
transport, thus exposing dopaminergic neurons to oxidative damage [132–134]. In further support to
oxidative stress-driven neuronal loss in PD is the finding of altered levels of glutathione in dopaminergic
neurons of transgenic mice, which indicates an impairment in antioxidant defenses in PD [135].
Sporadic forms of PD recapitulate all major hallmarks of aging, thus making PD a prototypical
geroscience condition [4,129]. The co-occurrence of mitochondrial dysfunction and neuroinflammation
are alleged pathogenic mechanisms of neuronal degeneration [24,136,137]. In particular, defective
MQC and DAMPs generation are proposed to be major contributing factors [52]. Indeed, the activation
of innate immunity and the consequent inflammation triggered by impaired autophagy and insufficient
clearance of damaged mitochondria have been reported in mice depleted of Pink1 or parkin gene
(PARK2) [52]. The control of mitophagy over inflammation operates also via the mitophagy mediator
Parkin [138]. In particular, Parkin regulates adaptive immunity via mitochondrial antigens presentation
to endosomes where they are loaded onto major histocompatibility complex class I molecules [138].
A role similar to mitochondrial antigen presentation is exerted by the intracellular trafficking regulator
RAB7A by controlling the fusion of MDVs with late endosomes for subsequent cargo degradation [138].
This additional role of RAB7A ensures mitochondrial antigen presentation in immune cells via MDV
trafficking even in the absence of PINK1 or Parkin [138]. Indeed, a decline in PINK1/Parkin expression
and activity in PD is implicated in MQC disruption and neuroinflammation via MDV-mediated
mitochondrial antigen presentation [138].
Although several lines of evidence indicate a possible link between mitochondrial damage and
inflammatory and metabolic disarrangements in PD [137,139], the molecular events the control the
sensing of neuronal mitochondrial dysfunction and protein dyshomeostasis at the systemic level are
presently unknown. The presence of mitochondrial DAMPs in circulating EVs has been described in
older adults with PD and is characterized by a specific inflammatory signature [113]. In particular,
higher serum concentrations of small EVs have been found in older people with PD [113]. These
EVs included exosomes of endosomal origin that contain mitochondrial signatures [113]. However,
after normalizing for the overall serum EV content, people with PD showed lower levels of MDVs
relative to non-PD controls [113]. This lower secretion of MDVs in older adults with PD supports
the hypothesis of mitochondrial dysfunction secondary to stalling of MQC system [113], especially if
considering that the generation of MDV is proposed to be a housekeeping mechanism complementing
MQC for preserving cell homeostasis [140].
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While placing mitochondrial dysfunction and inflammation among the relevant mechanisms
contributing to PD, the analysis of a comprehensive sets of markers and multi-platform statistical
approach are needed for capturing PD complexity. Following this strategy, a molecular roadmap
including mediators related to MDVs and inflammation has been identified [113]. Among the
ever-growing list of molecules linking the two processes, the fibroblast growth factor 21 (FGF21) was
associated with PD [113]. Due to its association with impaired MQC in neurons of murine models
of tauopathy and prion disease, FGF21 has been indicated as a “mitokine” [141]. Although further
analysis in longitudinal cohorts is needed to confirm the discriminatory power of these mediators as
PD biomarkers, these findings suggest that scavenging mitochondrial DAMPs, including mtDNA,
may offer therapeutic gain in PD.
5. Down Syndrome
DS (trisomy 21) is caused by a genetic abnormality and is marked by several features, including
cognitive impairment, peculiar craniofacial appearance, gastrointestinal abnormalities, congenital
heart defects, and neurological, endocrine and immune disorders [142]. People with DS have shorter
lifespan than the general population and DS has mostly been studied as a pediatric condition [142].
However, in light of the increased life expectancy of people with DS, it has become clear that DS is no
longer manageable as a pediatric condition [143,144]. When comparing biological vs. chronological
age, people with DS age earlier and faster than age-matched controls. Such an accelerated aging is
characterized by the early appearance of several phenotypes, including skin wrinkling, graying and loss
of hair, visual impairments, early menopause, high prevalence of AD [145], and multimorbidity [146].
These features indicate that DS is a segmental progeroid syndrome [147]. The identification of mediators
associated with the occurrence of aging-like phenotypes may therefore represent a powerful tool
for the development of effective therapeutic interventions aimed at delaying aging and extending
life expectancy.
A set of mediators pertaining to the so-called hallmarks of aging (i.e., DNA methylation, telomere
attrition, deregulated nutrient sensing, and immunosenescence) are altered in persons with DS and are
invoked as mechanisms involved in premature aging [148–150]. When considering the clinical features
of DS, attention has been paid to cognitive deficits especially because of their impact on quality of life
and prognosis [151,152]. However, musculoskeletal abnormalities have also been described in DS and
may contribute to declining physical performance [153,154].
Oxidative stress is a hallmark of segmental progeroid conditions. In DS, this is mainly
ascribed to genetic imbalance of chromosome 21, which contains, among others, genes implicated in
antioxidant defense, especially SOD1 [11,12]. The supplementation with two natural polyphenols
(i.e., epigallocatechin-3-gallate and resveratrol) has shown to counteract oxidative stress in hippocampal
progenitor cells from a mouse model of DS via restoring the efficiency of oxidative phosphorylation
and stimulating mitochondrial biogenesis [155].
Mitochondrial dysfunction has been described in pre-clinical models of DS and in primary cell
cultures from people with DS and proposed as a major factor in DS pathogenesis [12,156]. In particular,
mitochondrial ROS overproduction has been detected in human skin fibroblasts with trisomic karyotype
and has been associated with deficit in mitochondrial complex I, ATP synthase, ADP/ATP translocator,
and adenylate kinase activities [157,158]. Mitochondrial DNA mutations and alteration in mtDNA
repair systems have also been reported in fibroblasts from persons with DS and DS brain tissue [159,160].
Induced pluripotent stem cells (iPSCs) from people with DS and iPSCs-derived DS neurons show
oxidative hallmarks and are more sensitive to oxidative damage than control cells [161,162]. Fragmented
and bioenergetically inefficient mitochondria have also been observed in DS as a result of impaired
MQC [163]. Along with these changes, signs of premature immunosenescence (i.e., lower activity
of natural killer cells, reduced repertoire of T and B lymphocytes, telomere erosion in lymphocytes,
and increased risk of developing autoimmune disorders) and a pro-inflammatory profile characterize
people with DS [164,165].
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However, the pathways involved in the genesis of the pro-oxidant milieu and their intersection
with other age-related hallmarks, such as chronic, low-grade inflammation and MQC alterations in DS
remain uninvestigated.
6. Potential Therapeutics to Counteract Neuroinflammation
The identification of sterile inflammation as a common thread of neurodegenerative diseases
has instigated the exploration of pathways involved in innate immunity for the identification of
targets amenable for interventions. Indeed, while the release of DAMPs is protective by promoting
tissue repair, uncontrolled DAMPs production and consequent hyper-activation of PRRs can lead
to neuroinflammation. Therefore, the possibility to target DAMPs and their downstream signaling
molecules has been explored as a therapeutic option to attenuate neuroinflammation.
The neutralization of TLR2 and TLR4 via anti-TLR2 and anti-TLR4 antibodies has shown to block
the immune response to fibrillar Aβ(1-42) aggregates in AD models [166]. Also, the abrogation of IL1β
production by MCC950, a selective NLRP3 inhibitor, or the blockade of IL1 receptor attenuates the
propagation of neuroinflammation [167,168], preserves dopaminergic neurons of the substantia nigra,
and alleviates motor deficits [169].
Immunotherapeutic approaches have also shown potential against PD [170]. These approaches
target α-synuclein by reducing or preventing its intracellular accumulation and intercellular
transmission [170]. Anti-inflammatory drugs and immunosuppressants limit α-synuclein accrual in PD
by inhibiting the release of pro-inflammatory cytokines, restoring lysosome function, and accelerating
α-synuclein clearance (reviewed in [170]). Various types of T cells implicated in PD pathogenesis
may represent another therapeutic target in PD. In particular, counteracting the development of TH17
cells, known killers of dopaminergic neurons, or blocking the release of IL17 has been proposed as a
therapeutic option in PD [171].
Resveratrol, a natural polyphenol with anti-inflammatory properties, is currently in clinical
trials for AD. This compound mitigates microglia activation by inhibiting TLR4/NF-κB/signal
transducer and activator of transcription signaling, and cytokine release upon Aβ stimulation in
preclinical models of AD [172]. Epigallocatechin-3-gallate, another well-known natural polyphenol,
and resveratrol have also been proposed for the management of DS. In vitro experiments have
shown that epigallocatechin-3-gallate is a potent ROS scavenger and an antiapoptotic agent [173].
Among the neuroprotective effects of epigallocatechin-3-gallate are also the activation of mitochondrial
biogenesis and the preservation of mitochondrial bioenergetics via Sirtuin 1/AMPK/peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) signaling [155,174–176].
The administration of metformin, a drug commonly used for the treatment of type 2 diabetes, has been
shown to activate PGC-1α and has been proposed as a potential pharmacological strategy in DS [177].
Indeed, fibroblasts from DS human fetuses treated with metformin showed cristae remodeling and
improvement in mitochondrial plasticity and bioenergetics [177]. Finally, melatonin has been proposed
as a therapeutic option in DS due to its neuroprotective and anti-neuroinflammatory effects [178].
Melatonin is a modulator of neuronal mitochondrial integrity during aging [178]. However, its efficacy
and safety for the management of neuroinflammation warrants investigation.
7. Conclusions
Neuroinflammation is a common thread of neurodegenerative disorders. Along with this,
mitochondrial dysfunction and derangements in quality control pathways represent major contributors to
the accrual of oxidized components within the cells. With the intent of disposing dysfunctional components
and unclogging the degradative endo-lysosomal system, cells may unload damaged constituents, including
fragmented or whole mitochondria, in the extracellular space. Here, the interaction between bacterial-like
motifs of mtDNA and cells of innate immunity may trigger inflammation. Thus, an enhancement of EV
secretion can be a protective strategy as it may help alleviate the disruption of the endosomal–lysosomal
system in disease-vulnerable neurons. The characterization of the cargo of these EVs may assist in
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clarifying the pathways involved in neuronal degeneration and support the development of therapeutic
approaches sustaining neuronal exosome biogenesis in the setting of several neurodegenerative disorders.
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